These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 18024377)

  • 1. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of VWF in the immunogenicity of FVIII.
    Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
    Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.
    Turecek PL; Gritsch H; Richter G; Auer W; Pichler L; Schwarz HP
    Thromb Haemost; 1997 Mar; 77(3):591-9. PubMed ID: 9066015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
    [No Abstract]   [Full Text] [Related]  

  • 11. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
    Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.
    Reipert BM; Ahmad RU; Turecek PL; Schwarz HP
    Thromb Haemost; 2000 Nov; 84(5):826-32. PubMed ID: 11127864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
    Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
    Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.